Publicacións nas que colabora con N. Fernández Núñez (12)

2024

  1. Outcomes and patterns of use of Radium-223 in metastatic castration-resistant prostate cancer

    Frontiers in Oncology, Vol. 14

2022

  1. Real-world data with afatinib in Spanish patients with treatment-naïve non-small-cell lung cancer harboring exon 19 deletions in epidermal growth factor receptor (Del19 EGFR): Clinical experience of the Galician Lung Cancer Group

    Cancer Treatment and Research Communications, Vol. 33

2021

  1. Efficacy and safety of Nivolumab in older patients with pretreated lung cancer: A subgroup analysis of the Galician lung cancer group

    Journal of Geriatric Oncology, Vol. 12, Núm. 3, pp. 410-415

  2. Rethinking prognostic factors in locally advanced or metastatic urothelial carcinoma in the immune checkpoint blockade era: a multicenter retrospective study

    ESMO open, Vol. 6, Núm. 2, pp. 100090

2020

  1. A new scenario in metastatic renal cell carcinoma: a SOG-GU consensus

    Clinical and Translational Oncology, Vol. 22, Núm. 9, pp. 1565-1579

  2. PD-(L)1 inhibitors in combination with chemotherapy as first-line treatment for non-small-cell lung cancer: A pairwise meta-analysis

    Journal of Clinical Medicine, Vol. 9, Núm. 7, pp. 1-13

2019

  1. Chemotherapy management for unfit patients with metastatic castration-resistant prostate cancer

    Clinical and Translational Oncology, Vol. 21, Núm. 3, pp. 249-258

  2. Evaluation of the lung immune prognostic index in advanced nonsmall cell lung cancer patients under nivolumab monotherapy

    Translational Lung Cancer Research, Vol. 8, Núm. 6, pp. 1078-1085

2015

  1. Erlotinib as second-line therapy for patients with advanced non-small-cell lung cancer and wild-type EGFR tumors

    Journal of Analytical Oncology, Vol. 4, Núm. 3, pp. 94-101

2013

  1. Importancia de los distintos tipos histológicos en el CPNCP

    Revisiones en Cancer

  2. The role of platinum compounds for the treatment of breast cancer

    Current Breast Cancer Reports, Vol. 5, Núm. 1, pp. 11-22

  3. ¿bevacizumab hasta la progresión?

    Revisiones en Cancer, Vol. 27, pp. 102-105